HER2低表达作为潜在独立
分子亚型的生物学特点研究
01
抗体偶联药物(ADC)在HER2
低表达转移性乳腺癌的应用
02
参考文献 向上滑动阅览
[1] Shui R,Liang X,Li X,et al.Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma:A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.Clin Breast Cancer.2020;20(1):e65-e74.
[2] Zhang G,Ren C,Li C,Wang Y,Chen B,Wen L,Jia M,Li K,Mok H,Cao L,Chen X,Lin J,Wei G,Li Y,Zhang Y,Balch CM,Liao N.Distinct clinical and somatic mutational features of breast tumors with high-,low-,or non-expressing human epidermal growth factor receptor 2 status.BMC Med.2022 Apr 29;20(1):142.doi:10.1186/s12916-022-02346-9.PMID:35484593;PMCID:PMC9052533.
[3] Paolo Tarantino et al.2022 ESMO-Breast Cancer
[4] Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;10.1056/NEJMoa2203690.
END
联系客服